Compile Data Set for Download or QSAR
Report error Found 92 Enz. Inhib. hit(s) with Target = 'Apoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide'
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571527((rac)-(rac-15)-benzyl-4-chloro-3-ethyl-7-{3-[(6-fl...)
Affinity DataIC50: 1.22E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571495((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.32E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571496((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.41E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571472((−)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{...)
Affinity DataIC50: 1.46E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571475((+)-4-chloro-15-cyclopropyl-3-ethyl-7-{3-[(6-fluor...)
Affinity DataIC50: 1.51E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571488((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.59E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571469((+)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1-...)
Affinity DataIC50: 1.63E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571474((rac)-4-chloro-(15-rac)-cyclopropyl-3-ethyl-7-{3-[...)
Affinity DataIC50: 1.63E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572222(US11447504, Example 79 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 1.70E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571489((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 1.70E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571470((−)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphtha...)
Affinity DataIC50: 1.78E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571477((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.81E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571476((−)-4-chloro-15-cyclopropyl-3-ethyl-7-{3-[(6...)
Affinity DataIC50: 1.83E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571463((rac)-4-Chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-...)
Affinity DataIC50: 1.86E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572202(US11478451, Example 086 | (rac)-4-chloro-12,12-dif...)
Affinity DataIC50: 1.88E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572219(US11447504, Example 76 | US11447504, Example 75 | ...)
Affinity DataIC50: 1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572219(US11447504, Example 76 | US11447504, Example 75 | ...)
Affinity DataIC50: 1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571479((−)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthal...)
Affinity DataIC50: 1.93E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571510((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.96E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571485((rac)-3-Ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571481((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571482((−)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthal...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571483((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571491((rac)-4-chloro-(15-rac)-[2-(3,3-difluoropyrrolidin...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571480((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571478((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571473((rac)-4-chloro-(15-rac)-(2-methoxyethyl)-2,3-dimet...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571471((+)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{3-[(na...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571468((−)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethy...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571467((+)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571507((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572166(US11478451, Example 21 | (rac)-4-chloro-3-ethyl-2-...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572165((rac)-(11 Z)-4-chloro-3-ethyl-2-methyl-7-[3-(napht...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572161(US11478451, Example 16 | US11447504, Example 16 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572162(US11478451, Example 17 | (+)-4-chloro-7-{3-[(6-flu...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572159((+)-4-chloro-2,3,14-trimethyl-7-[3-(naphthalen-1-y...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572155((rac)-4-chloro-3-ethyl-1-[2-(morpholin-4-yl)ethyl]...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572152(US11478451, Example 7 | (rac)-4-chloro-3-ethyl-7-{...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572149(US11478451, Example 4 | rac-4-chloro-1,3-dimethyl-...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572148(US11478451, Example 1 | (rac)-(11Z)-4-chloro-1,3-d...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571486((+)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571504(4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)ox...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571501((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571498((−)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthal...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571491((rac)-4-chloro-(15-rac)-[2-(3,3-difluoropyrrolidin...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571491((rac)-4-chloro-(15-rac)-[2-(3,3-difluoropyrrolidin...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571464((rac)-4-Chloro-15-cyclopropyl-2,3-dimethyl-7-{3-[(...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571490((−)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthal...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571487((−)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthal...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572198(US11478451, Example 52 | (rac)-4-chloro-3-ethyl-2-...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 92 total ) | Next | Last >>
Jump to: